Invesco Biotechnology & Genome ETF
PBE
64 hedge funds and large institutions have $52.9M invested in Invesco Biotechnology & Genome ETF in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 6 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 16
3% less capital invested
Capital invested by funds: $54.4M → $52.9M (-$1.47M)
1.63% less ownership
Funds ownership: 23.27% → 21.64% (-1.6%)
6% less funds holding
Funds holding: 68 → 64 (-4)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$639K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$637K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$527K |
| 4 |
MML Investors Services
Springfield,
Massachusetts
|
+$511K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$338K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
-$5.83M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.38M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$954K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$453K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$412K |
PBE Hedge Fund Activity: Q2 2017 in Review
64 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2017, worth a combined $52.9M — down 2.7% from $54.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PBE and 4 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 21 added.
The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $639K. The largest seller was Stifel Financial, cutting an estimated $5.83M.
- 64 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2017, down from 68 in Q1 2017.
- Funds reported $52.9M of Invesco Biotechnology & Genome ETF stock for Q2 2017, down 2.7% quarter-over-quarter.
- 4 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2017 and 6 closed out, a net change of -2 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2017 was Ladenburg Thalmann Financial Services, an estimated $639K added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2017 was Stifel Financial, an estimated $5.83M sold.
Based on aggregated 13F filings for Q2 2017.